Appia Bio
Edmund Kim, PhD, is co-founder and COO. He comes from Kite Pharma where was vice president of corporate development. At Kite, Edmund was responsible for cell therapy business development and a member of Kite’s leadership team following its acquisition by Gilead in 2017. Previously, he was senior director of global business development at Mylan NV (now Viatris), and an equity research analyst at J.P. Morgan Securities covering specialty pharmaceutical stocks. Edmund received a PhD in immunology from Weill Cornell Graduate School of Medical Sciences and a BA in molecular biology from Pomona College.
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).